Increased atherogenicity in mood disorders: a systematic review, meta-analysis and meta-regression
Authors:
- Ketsupar JirakranKJKetsupar Jirakran
- Abbas F. AlmullaAbbas F. Almulla
- Thapanee JaipintaTJThapanee Jaipinta
- Asara VasupanrajitAVAsara Vasupanrajit
- Priabprat JansemPJPriabprat Jansem
- Chavit TunvirachaisakulCTChavit Tunvirachaisakul
- Elizabet DzhambazovaEDElizabet Dzhambazova
- Drozdstoj St. StoyanovDrozdstoj St. Stoyanov
- Michael MaesMMMichael Maes
Preprint
Abstract
Background Major depressive disorder (MDD) and bipolar disorder (BD) often coexist with metabolic syndrome. Both are linked to increased atherogenicity and a higher risk of cardiovascular diseases. Objectives This meta-analysis seeks to evaluate the relationship between atherogenic indices and mood disorders (MDD/BD), while identifying the most effective atherogenic biomarkers for mood disorders. Methods This study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We searched electronic databases, including PubMed, Google Scholar, and Web of Science, for articles published up to August 1, 2024. Results In this meta-analysis, 85 eligible studies (14 on BD and 71 on MDD) were included, covering 70,856 participants: 18,738 patients and 52,118 healthy controls. Patients with mood disorders showed significant increases (p < 0.001) in the Castelli Risk Index 2 (CRI2), Atherogenic Index of Plasma (AIP), and (triglyceride or TG + low-density lipoprotein + very low-density lipoprotein)/(high-density lipoprotein cholesterol or HDL + Apolipoprotein A or ApoA) ratio, but not CRI1 and ApoB/ApoA ratio. Significant lower HDL and lecithin: cholesterol acyltransferase activity, and higher TG levels were observed in mood disordered patients compared with controls. There were no significant differences between MDD and BD patients. Most included studies lacked the most essential information on the inclusion and exclusion of important confounders. Conclusions AIP is the most effective atherogenicity index for mood disorders. Regular lipid profiling and metabolic syndrome screening are crucial in mood disorders. Early intervention with lipid-lowering therapies is recommended to prevent the worsening of atherogenicity and disease progression.Keywords
All Related Versions
- Published version: Neuroscience & Biobehavioral Reviews, 169, 106005.
This publication has 100 references indexed in Scilit:
- Reverse cholesterol transport and lipid peroxidation biomarkers in major depression and bipolar disorder: A systematic review and meta-analysisBrain, Behavior, and Immunity, 2023
- Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Levels in Adolescent with Bipolar Disorder and Their Relationship with Metabolic ParametersJournal of Molecular Neuroscience, 2022
- Cochrane Handbook for Systematic Reviews of Interventions2019
- Mortality in Mental Disorders and Global Disease Burden ImplicationsJAMA Psychiatry, 2015
- Depression, anxiety disorders, and metabolic syndrome in a population at risk for type 2 diabetes mellitusBrain and Behavior, 2015
- Staging and Neuroprogression in Bipolar DisorderCurrent Psychiatry Reports, 2012
- IL-1β, IL-6, IL-8, IL-10, IFN-γ, TNF-α and its relationship with lipid parameters in patients with major depressionMetabolic Brain Disease, 2012
- Depression in Relation to Long-term Control of Glycemia, Blood Pressure, and Lipids in Patients with DiabetesJournal of General Internal Medicine, 2010
- The relationship between cholesterol levels and depression in the elderlyInternational Journal of Geriatric Psychiatry, 2004
- Serum cholesterol and depressive symptoms in elderly Finnish menInternational Journal of Geriatric Psychiatry, 2002